首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1871510

2021-2031年歐洲人類微生物組市場報告：範圍、細分、動態和競爭分析

Europe Human Microbiome Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

出版日期: 2025年09月01日 | 出版商:

The Insight Partners | 英文 140 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

歐洲人類微生物組市場預計將大幅成長，到 2031 年將達到約 9.9966 億美元，高於 2023 年的 2.0479 億美元，反映出 2023 年至 2031 年的年複合成長率(CAGR) 為 21.9%。

執行摘要和市場分析

市場主要分為以下幾個區域：法國、德國、英國和歐洲其他地區。歐洲在全球人類微生物組市場中扮演著至關重要的角色，預計在2023年至2031年期間將實現強勁成長。這一成長主要得益於針對人類微生物組的研究項目增加以及慢性疾病和紊亂的增加。此外，與人類微生物組相關的各項研究計畫的拓展預計也將成為推動歐洲市場成長的主要因素。

市場區隔分析

歐洲人類微生物組市場可以透過幾個關鍵細分市場進行分析：類型、應用和疾病類型。

按類型分類：市場分為產品和軟體/服務兩類。 2023年，產品類市場佔據主導地位，其中產品類又可細分為益生菌及益生元。
按應用領域分類：市場分為治療、診斷和研究，其中治療領域在 2023 年佔據最大的市場佔有率。
按疾病類型分類：市場分為肥胖症、糖尿病、自體免疫疾病、癌症、胃腸道 (GIT) 問題等類別，其中 GIT 議題在 2023 年將引領市場。

市場展望

人類微生物組產業的成長和動態受到主要市場參與者投資的顯著影響。這些公司大力投資研發，以開發創新益生菌、診斷方法和基於微生物組的療法。此類投資促進了創新，從而發現了新的菌株、作用機制和治療應用。臨床試驗需要大量資金，但對於驗證微生物組相關產品的安全性和有效性至關重要。

例如，微生物組圖譜技術領域的領導企業 Kanvas Biosciences 在 2023 年 6 月的 Pre-A 輪融資中獲得了 1,200 萬美元。這筆資金將用於推動其專有平台技術的研發，旨在革新微生物組相關疾病的藥物開發。此外，企業間的合作能夠加強資源共享、專業知識交流和技術進步，進而加速產品開發。 2023 年 7 月，全球最大的食品飲料公司雀巢與領先的研究中心 APC Microbiome Ireland 建立了重要的合作夥伴關係，雙方將致力於研究人類微生物組的各個方面，以開發新的健康促進產品。目前，約有 120 家公司正在投資微生物組分析，並且有許多新創公司正在湧入該領域。主要投資者包括 Flagship Pioneering、Seventure Partners 和 BioGaia，這表明這些投資者的持續投入有望推動市場成長。

國家概況

歐洲人類微生物組市場涵蓋英國、德國、法國、義大利、西班牙等國。德國在2023年成為最大的市場，被公認為歐洲乃至全球重要的生物技術研究中心。這主要歸功於德國擁有許多大型生物技術公司、先進的研究設施以及雄厚的研發資金。德國持續的研發活動和有利於微生物組療法開發的政府法規，為該領域帶來了巨大的發展機會。例如，2022年，由沃爾夫博士集團（Dr. Wolff Group）生產的Vagisan ProbioFlora被重新分類並獲得藥品資格，這對整個以微生物組為驅動的製藥行業產生了積極影響。

2023年3月，mbiomics GmbH宣布成功完成A輪融資首輪交割，籌集資金1300萬歐元（約1500萬美元），由MIG Capital領投，High-Tech Grunderfonds、Bayern Kapital及私人投資者參投。 mbiomics利用其專有的高解析度分析平台，設計用於精準治療的有效微生物群落，並改善臨床試驗中的患者篩選和監測。

公司簡介

人類微生物組市場的主要參與者包括 MaaT Pharma、Ferring Holdings SA、AOBiome Therapeutics Inc、Finch Therapeutics Group Inc、Seres Therapeutics Inc、Merck & Co Inc、Rebiotix, Inc.、Yakult Honsha Co., Ltd.、IFF Nutrition & Biosciences 和 Synthetic Biologics, Inc.。這些公司正在採用各種策略，例如擴張、產品創新以及併購，以增強其產品供應並提高市場佔有率。

The market is divided into key regions: France, Germany, the UK, and the Rest of Europe. Europe plays a crucial role in the global human microbiome market and is anticipated to experience strong growth during the period from 2023 to 2031. This growth is driven by an increase in research studies focused on the human microbiome and a rise in chronic diseases and disorders. Additionally, the expansion of various research initiatives related to human microbiomes is expected to be a primary factor propelling market growth in Europe.

Market Segmentation Analysis

The Europe human microbiome market can be analyzed through several key segments: type, application, and disease type.

By Type: The market is categorized into products and software/services. In 2023, the product segment dominated the market, which is further divided into probiotics and prebiotics.
By Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
By Disease Type: The market is classified into categories such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with GIT issues leading the market in 2023.

Market Outlook

The growth and dynamics of the human microbiome industry are significantly influenced by investments from major market players. These companies are heavily investing in research and development to create innovative probiotics, diagnostics, and microbiome-based treatments. Such investments foster innovation, leading to the discovery of new strains, mechanisms of action, and therapeutic applications. Clinical trials, which require substantial funding, are essential for validating the safety and efficacy of microbiome-related products.

For instance, Kanvas Biosciences, a leader in microbiome mapping technology, secured USD 12 million in a Pre-Series A funding round in June 2023. This funding will support the advancement of their proprietary platform technology aimed at revolutionizing drug development for microbiome-related diseases. Furthermore, collaborations among companies enhance resource sharing, expertise, and technological advancements, accelerating product development. A notable partnership was formed in July 2023 between Nestle, the largest food and beverage company globally, and APC Microbiome Ireland, a leading research center, focusing on various aspects of the human microbiome to develop new health-enhancing products. Currently, around 120 companies are investing in microbiome analysis, with numerous startups entering the sector. Key investors include Flagship Pioneering, Seventure Partners, and BioGaia, indicating that increased investment from these players is likely to drive market growth.

Country Insights

The European human microbiome market includes countries such as the UK, Germany, France, Italy, Spain, and others. Germany emerged as the largest market in 2023, recognized as a significant hub for biotechnological research in Europe and globally. This is attributed to the presence of major biotechnology firms, advanced research facilities, and substantial funding for research and development. The ongoing R&D activities and favorable government regulations for microbiome therapeutics development in Germany present lucrative opportunities. For example, in 2022, Vagisan ProbioFlora, produced by Dr. Wolff Group, was reclassified and received medicinal product status, positively impacting the broader microbiome-driven pharmaceutical industry.

In March 2023, mbiomics GmbH announced a successful first closing of its Series A financing round, raising EUR 13 million (approximately USD 15 million), led by MIG Capital with participation from High-Tech Grunderfonds, Bayern Kapital, and private investors. Mbiomics utilizes its proprietary high-resolution profiling platform to design effective microbial consortia for precision therapies and improve patient selection and monitoring in clinical trials.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their product offerings and increase market share.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Europe Human Microbiome Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Europe Human Microbiome Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Significant Investments by Key Market Players
- 5.1.2 Government Initiatives
5.2 Market Restraints
- 5.2.1 Challenges During Production of Microbiome
5.3 Market Opportunities
- 5.3.1 Robust Investment in Research and Development
5.4 Future Trends
- 5.4.1 Emergence of Precision Medicine
5.5 Impact of Drivers and Restraints:

6. Human Microbiome Market - Europe Analysis

6.1 Europe Human Microbiome Market Revenue (US$ Million), 2021-2031
6.2 Europe Human Microbiome Market Forecast Analysis

7. Europe Human Microbiome Market Analysis - by Type

7.1 Product
- 7.1.1 Overview
- 7.1.2 Product: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Software and Services
- 7.2.1 Overview
- 7.2.2 Software and Services: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Human Microbiome Market Analysis - by Application

8.1 Therapeutics
- 8.1.1 Overview
- 8.1.2 Therapeutics: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Diagnostics
- 8.2.1 Overview
- 8.2.2 Diagnostics: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Research
- 8.3.1 Overview
- 8.3.2 Research: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Human Microbiome Market Analysis - by Disease Type

9.1 Obesity
- 9.1.1 Overview
- 9.1.2 Obesity: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Diabetes
- 9.2.1 Overview
- 9.2.2 Diabetes: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Autoimmune Disorder
- 9.3.1 Overview
- 9.3.2 Autoimmune Disorder: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.4 Cancer
- 9.4.1 Overview
- 9.4.2 Cancer: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.5 GIT
- 9.5.1 Overview
- 9.5.2 GIT: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Human Microbiome Market - Country Analysis

10.1 Europe
- 10.1.1 Europe Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.1 Europe Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.2 United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.2.1 United Kingdom: Europe Human Microbiome Market Share - by Type
    - 10.1.1.2.2 United Kingdom: Europe Human Microbiome Market Share - by Product
    - 10.1.1.2.3 United Kingdom: Europe Human Microbiome Market Share - by Application
    - 10.1.1.2.4 United Kingdom: Europe Human Microbiome Market Share - by Disease Type
  - 10.1.1.3 Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.3.1 Germany: Europe Human Microbiome Market Share - by Type
    - 10.1.1.3.2 Germany: Europe Human Microbiome Market Share - by Product
    - 10.1.1.3.3 Germany: Europe Human Microbiome Market Share - by Application
    - 10.1.1.3.4 Germany: Europe Human Microbiome Market Share - by Disease Type
  - 10.1.1.4 France: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.4.1 France: Europe Human Microbiome Market Share - by Type
    - 10.1.1.4.2 France: Europe Human Microbiome Market Share - by Product
    - 10.1.1.4.3 France: Europe Human Microbiome Market Share - by Application
    - 10.1.1.4.4 France: Europe Human Microbiome Market Share - by Disease Type
  - 10.1.1.5 Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.5.1 Italy: Europe Human Microbiome Market Share - by Type
    - 10.1.1.5.2 Italy: Europe Human Microbiome Market Share - by Product
    - 10.1.1.5.3 Italy: Europe Human Microbiome Market Share - by Application
    - 10.1.1.5.4 Italy: Europe Human Microbiome Market Share - by Disease Type
  - 10.1.1.6 Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.6.1 Spain: Europe Human Microbiome Market Share - by Type
    - 10.1.1.6.2 Spain: Europe Human Microbiome Market Share - by Product
    - 10.1.1.6.3 Spain: Europe Human Microbiome Market Share - by Application
    - 10.1.1.6.4 Spain: Europe Human Microbiome Market Share - by Disease Type
  - 10.1.1.7 Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.7.1 Rest of Europe: Europe Human Microbiome Market Share - by Type
    - 10.1.1.7.2 Rest of Europe: Europe Human Microbiome Market Share - by Product
    - 10.1.1.7.3 Rest of Europe: Europe Human Microbiome Market Share - by Application
    - 10.1.1.7.4 Rest of Europe: Europe Human Microbiome Market Share - by Disease Type

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Human Microbiome Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 MaaT Pharma
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Ferring Holdings SA
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 AOBiome Therapeutics Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Finch Therapeutics Group Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Financial Overview
- 12.4.4 SWOT Analysis
- 12.4.5 Key Developments
12.5 Seres Therapeutics Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Merck & Co Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Yakult Honsha Co., Ltd.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Rebiotix, Inc.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 IFF Nutrition & Biosciences
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Synthetic Biologics, Inc.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 List of Abbreviations

簡介目錄圖表

List Of Tables

Table 1. Europe Human Microbiome Market Segmentation
Table 2. Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Table 3. Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Type
Table 4. Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Application
Table 5. Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Disease Type
Table 6. Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
Table 7. United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 8. United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 9. United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 10. United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 11. Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 12. Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 13. Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 14. Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 15. France: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 16. France: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 17. France: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 18. France: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 19. Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 21. Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 22. Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 23. ADULT OBESITY, 2030
Table 24. CHILD OBESITY, 2030
Table 25. Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 26. Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 27. Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 28. Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 29. Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 30. Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 31. Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 32. Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 33. Recent Organic Growth Strategies in the Human Microbiome Market
Table 34. Recent Inorganic Growth Strategies in the Human Microbiome Market
Table 35. List of Abbreviations

List Of Figures

Figure 1. Europe Human Microbiome Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Europe Human Microbiome Market - Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Europe Human Microbiome Market Revenue (US$ Million), 2021-2031
Figure 6. Europe Human Microbiome Market Share (%) - by Type (2023 and 2031)
Figure 7. Product: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 8. Software and Services: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 9. Europe Human Microbiome Market Share (%) - by Application (2023 and 2031)
Figure 10. Therapeutics: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 11. Diagnostics: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 12. Research: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 13. Europe Human Microbiome Market Share (%) - by Disease Type (2023 and 2031)
Figure 14. Obesity: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 15. Diabetes: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 16. Autoimmune Disorder: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 17. Cancer: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 18. GIT: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 19. Others: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 20. Europe Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 21. United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 22. Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 23. France: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 24. Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 25. Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 26. Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 27. Growth Strategies in the Human Microbiome Market